M
Minori Koshiji
Researcher at Merck & Co.
Publications - 53
Citations - 13477
Minori Koshiji is an academic researcher from Merck & Co.. The author has contributed to research in topics: Pembrolizumab & Cancer. The author has an hindex of 23, co-authored 53 publications receiving 10863 citations. Previous affiliations of Minori Koshiji include ImClone Systems & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le,Jennifer N. Uram,Hao Wang,Bjarne Bartlett,Holly Kemberling,Aleksandra Eyring,Andrew D. Skora,Brandon Luber,Nilofer S. Azad,Daniel A. Laheru,Barbara A. Biedrzycki,Ross C. Donehower,Atif Zaheer,George A. Fisher,Todd S. Crocenzi,James J. Lee,Steven M. Duffy,Richard M. Goldberg,Richard M. Goldberg,Albert de la Chapelle,Albert de la Chapelle,Minori Koshiji,Feriyl Bhaijee,Thomas Huebner,Ralph H. Hruban,Laura D. Wood,Nathan Cuka,Drew M. Pardoll,Nickolas Papadopoulos,Kenneth W. Kinzler,Shibin Zhou,Toby C. Cornish,Janis M. Taube,Robert A. Anders,James R. Eshleman,Bert Vogelstein,Luis A. Diaz +36 more
TL;DR: This study showed that mismatch-repair status predicted clinical benefit of immune checkpoint blockade with pembrolizumab, and high somatic mutation loads were associated with prolonged progression-free survival.
Journal ArticleDOI
PD-1 blockade in tumors with mismatch repair deficiency.
Dung T. Le,Jennifer N. Uram,Hao Wang,Bjarne Bartlett,Holly Kemberling,Aleksandra Eyring,Andrew D. Skora,Nilofer S. Azad,Daniel A. Laheru,Ross C. Donehower,Brandon Luber,Todd S. Crocenzi,George A. Fisher,Steve M Duffy,James J. Lee,Minori Koshiji,James R. Eshleman,Robert A. Anders,Bert Vogelstein,Luis A. Diaz +19 more
TL;DR: MM status predicts clinical benefit of immune checkpoint blockade with pembrolizumab, and high total somatic mutation loads were associated with PFS.
Journal ArticleDOI
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs,Jiri Tomasek,Cho Jae Yong,Filip Dumitru,Rodolfo Passalacqua,Chanchal Goswami,Howard Safran,Lucas Vieira dos Santos,G. Aprile,David Ferry,Bohuslav Melichar,Mustapha Tehfe,Eldar Topuzov,John Zalcberg,John Zalcberg,Ian Chau,William Campbell,Choondal Sivanandan,Joanna Pikiel,Minori Koshiji,Yanzhi Hsu,Astra M. Liepa,Ling Gao,Jonathan D. Schwartz,Josep Tabernero +24 more
TL;DR: Ramucirumab is the first biological treatment given as a single drug that has survival benefits in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma progressing after first-line chemotherapy, and validate VEGFR-2 signalling as an important therapeutic target in advanced Gastric cancer.
Journal ArticleDOI
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro,Hyun Cheol Chung,Veena Shankaran,Ravit Geva,Daniel V.T. Catenacci,Shilpa Gupta,Joseph Paul Eder,Talia Golan,Dung T. Le,Barbara Burtness,Autumn J. McRee,Chia-Chi Lin,Kumudu Pathiraja,Jared Lunceford,Kenneth Emancipator,Jonathan Juco,Minori Koshiji,Yung-Jue Bang +17 more
TL;DR: In this population of patients with recurrent or metastatic PD-L1-positive gastric cancer, pembrolizumab had a manageable toxicity profile and promising antitumour activity, warranting further study in phase 2 and 3 trials.
Journal ArticleDOI
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
Takuji Okusaka,Kohei Nakachi,Akira Fukutomi,Norifumi Mizuno,Shinichi Ohkawa,A Funakoshi,Masato Nagino,Satoshi Kondo,S Nagaoka,J Funai,Minori Koshiji,Yoshihiro Nambu,Junji Furuse,Masaru Miyazaki,Yuji Nimura +14 more
TL;DR: Gemcitabine plus cisplatin combination therapy was found to be effective and well tolerated, suggesting that it could also be a standard regimen for Japanese patients.